Yoga for Aromatase Inhibitor-associated Joint Pain
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer, Orthopedic |
| Therapuetic Areas: | Oncology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2013 |
| End Date: | August 2016 |
Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study
The purpose of this study is to determine whether it might be practical and useful to
investigate the effectiveness of yoga classes in relieving joint pain associated with the
use of a class of medications known as aromatase inhibitors.
investigate the effectiveness of yoga classes in relieving joint pain associated with the
use of a class of medications known as aromatase inhibitors.
The study uses a single-arm design. All study participants will be assigned to an
intervention condition in which they participate in group Iyengar yoga classes for 90
minutes twice per week for 12 weeks (total of 24 classes). Study outcomes are assessed: 1)
following recruitment but prior to the first yoga class; and 2) within two weeks
post-intervention (follow-up). Additionally, a brief assessment of pain will be conducted
four weeks and eight weeks after the start of yoga classes.
intervention condition in which they participate in group Iyengar yoga classes for 90
minutes twice per week for 12 weeks (total of 24 classes). Study outcomes are assessed: 1)
following recruitment but prior to the first yoga class; and 2) within two weeks
post-intervention (follow-up). Additionally, a brief assessment of pain will be conducted
four weeks and eight weeks after the start of yoga classes.
Inclusion Criteria:
- Have been diagnosed with stage 0-III breast cancer
- Have completed local and/or adjuvant breast cancer therapy (with the exception of
hormonal therapy) at least one month previously
- Are post-menopausal defined as defined as no menses in the past 12 months
- Are currently prescribed an aromatase inhibitor (AI) medication (anastrozole,
letrozole, or exemestane) by a Moffitt-affiliated physician
- Report joint pain that started or worsened after initiation of AI medication
- Report worst pain score > 4 in the preceding week on an 11-point (0-10) numeric
rating scale
Exclusion Criteria:
- Have been diagnosed with another form of cancer (except nonmelanoma skin cancer) in
the last five years
- Have uncontrolled cardiac disease, pulmonary disease, or infectious disease
- Have physical symptoms or conditions that could make yoga unsafe (i.e., neck
injuries, dizziness, shortness of breath, chest pain, or severe nausea)
- Have a body mass index (BMI) > 40 kg/m^2 (based on difficulties severly obese
individuals may have with engaging in Iyengar yoga poses)
- Have joint pain attributed to inflammatory arthritic conditions (i.e., rheumatoid
arthritis, gout, pseudo-gout) per medical record or patient history
- Had surgery within the past 3 months
- Had injections of medication within the last 3 months to joint(s) currently painful
- Are currently using corticosteroids or opioid medications
- Are currently attending yoga classes
- Do not speak or read standard English
- Are scheduled or are planning to discontinue AI medication in the next 16 weeks
- Do not have sufficient access to the Internet to complete study assessments
We found this trial at
1
site
12902 USF Magnolia Dr
Tampa, Florida 33612
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Click here to add this to my saved trials
